Research programme: obesity therapy - Migenix
Alternative Names: MITO-3108; MX-3108Latest Information Update: 06 Jun 2007
At a glance
- Originator MIGENIX
- Class
- Mechanism of Action Methylmalonyl CoA mutase stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Obesity
Most Recent Events
- 30 Apr 2006 Discontinued - Preclinical for Obesity in USA (Parenteral)
- 18 Apr 2006 This programme is still in active development
- 25 May 2005 Preclinical trials in Obesity in USA (unspecified route)